BioMark Diagnostics Inc
SWB:20B
Intrinsic Value
The intrinsic value of one 20B stock under the Base Case scenario is 0.004 EUR. Compared to the current market price of 0.193 EUR, BioMark Diagnostics Inc is Overvalued by 98%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
BioMark Diagnostics Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
BioMark Diagnostics Inc
Balance Sheet Decomposition
BioMark Diagnostics Inc
Current Assets | 159.4k |
Cash & Short-Term Investments | 88.6k |
Receivables | 70.8k |
Non-Current Assets | 717.2k |
Long-Term Investments | 3.2k |
PP&E | 679.9k |
Other Non-Current Assets | 34.1k |
Free Cash Flow Analysis
BioMark Diagnostics Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
BioMark Diagnostics Inc
Revenue
|
155k
CAD
|
Operating Expenses
|
-2.1m
CAD
|
Operating Income
|
-2m
CAD
|
Other Expenses
|
56.3k
CAD
|
Net Income
|
-1.9m
CAD
|
20B Profitability Score
Profitability Due Diligence
BioMark Diagnostics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
BioMark Diagnostics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
20B Solvency Score
Solvency Due Diligence
BioMark Diagnostics Inc's solvency score is 20/100. The higher the solvency score, the more solvent the company is.
Score
BioMark Diagnostics Inc's solvency score is 20/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
20B Price Targets Summary
BioMark Diagnostics Inc
Dividends
Current shareholder yield for BUX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one 20B stock under the Base Case scenario is 0.004 EUR.
Compared to the current market price of 0.193 EUR, BioMark Diagnostics Inc is Overvalued by 98%.